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The Informed Cohort Oversight Board:
From Values to Architecture
Ingrid A. Holm* & Patrick L. Taylor**, ***
I. THE CONCEPT OF THE ICOB
Current guidelines for return of research results in genomic studies focus on protecting the participant from harm using criteria including analytic validity, clinical validity,
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actionability, and severity of the outcome.1 Historically, rules
supporting or prohibiting disclosure of individual research results employed such variables.2 However, the formulation of
these rules was based on interpretive projections from the life
experience of the rule-formulators and not on rigorouslycollected empirical data concerning, for example, the prevalence and degree of harm, let alone data elucidating harm’s dependence on other known or unknown variables that might be
practically important in refining a practical ethical rule concerning results disclosure.3 Thus communicating genomic research results has historically been opposed, by some, based on
an assumption that therapeutic misconceptions are inevitable,
that harm necessarily flows from a misconception and is unpreventable and incurable, and that such harm necessarily
outweighs any potential benefit, regardless of how benefit
might be conceived or measured.4
Such theorization omits a factor now widely accepted in
clinical ethics: the personhood of patients and research participants, as reflected in respect for their autonomy and consideration of their own formulations of benefit, harm, and acceptable
risk.5 That one must “protect” research participants from
“harm” by imposing on them the ex cathedra meanings that researchers or ethicists, without the benefit of empirical data
concerning research participants themselves, attach to such
terms has seemed to us to be an assumption worth identifying,
examining and potentially reconsidering. This is especially necessary, since acceptance of the assumption seems to rest on a
consequentialist or utilitarian analysis that is undefended theoretically and unsupported by research data from a wellconstructed study of the sort we would demand in other con-

1. See, e.g., Richard R. Fabsitz et al., Ethical and Practical Guidelines for
Reporting Genetic Research Results to Study Participants: Updated Guidelines
from a National Heart, Lung, and Blood Institute Working Group, 3
CIRCULATION CARDIOVASCULAR GENETICS 574, 575–78 (2010).
2. See, e.g., id.; Isaac S. Kohane & Patrick L. Taylor, Multidimensional
Results Reporting to Participants in Genomic Studies: Getting It Right 2 SCI.
TRANSLATIONAL MED. 1, 1–2 (2010).
3. See, e.g., Fabsitz et al., supra note 1 at 575–58; Kohane & Taylor,
supra note 2, at 1–2.
4. See Kohane & Taylor, supra note 2.
5. See Mark A. Rothstein, Tiered Disclosure Options Promote the
Autonomy and Well-Being of Research Subjects, 6 AM. J. BIOETHICS 20, 20–21
(2006).
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texts.
For this reason, we, among others, have argued that research should investigate whether the personal meaning of genomic information to participants,6 participant preferences,
and personal perspectives on utility7 should inform ethical
standards for return of research results. We have argued this
not as a conclusion but as a hypothesis: entertaining the hypothesis is justified on theoretical grounds, and exploring it requires empirical testing of practically implemented, precisely
stated ethical hypotheses. This suggested approach is in line
with novel approaches in bioethics, which recognize the dependence of ethical conclusions on empirically verifiable data to
the extent such data are made material by ethical theory, including examining the basic terms of traditional ethics in light
of actual human potential and aggregate human experience.8
With respect to providing research participants with personal genomic data derived from genomic research, our group
has embodied this participant-based approach in the “Informed
Cohort” model, a novel concept for genomic studies that addresses the issues of collecting genotype and phenotype data,
carrying out genomic studies, and returning research results to
participants based on their preferences.9 In an Informed Cohort, each participant provides clinical information and
biospecimens when they enroll, and are then given a web-based
Personally Controlled Health Record (PCHR).10 The PCHR allows communication between researchers and participants

6. See, e.g., id.; Kohane & Taylor, supra note 2; Vardit Ravitsky &
Benjamin S. Wilfond, Disclosing Individual Genetic Results to Research
Participants, 6 AM. J. BIOETHICS 8 (2006).
7. See Morris W. Foster, John J. Mulvihill, & Richard R. Sharp,
Evaluating the Utility of Personal Genomic Information, 11 GENETICS
MEDICINE 570 (2009); Scott Grosse et al., Personal Utility and Genomic
Information: Look Before You Leap, 11 GENETICS MEDICINE 57 (2009); Scott D.
Grosse, Lisa Kalman & Muin J. Khoury, Evaluation of the Validity and Utility
of Genetic Testing for Rare Diseases, in ADVANCES IN EXPERIMENTAL MED. &
BIOLOGY: RARE DISEASES EPIDEMOIOLOGY (Manuel Posada De La Paz &
Stephen C. Groft ed., v. 686, 2010) 115–31 (2010); Muin Khoury et al., The
Scientific Foundation for Personal Genomics: Recommendations from a
National Institutes of Health-Centers for Disease Control and Prevention
Multidisciplinary Workshop, 11 GENETICS MEDICINE 559 (2009).
8. See KWAME A. APPIAH, EXPERIMENTS IN ETHICS (2008).
9. Isaac S. Kohane et al., Reestablishing the Researcher-Patient Compact,
316 SCI. 836, 836–37 (2007).
10. Id. at 837.
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without identifying participants to researchers.11 Through the
PCHR participants are able to manage a secure copy of their
medical data, update health information, refine phenotypic data, contribute additional biomaterials, and receive messages including general messages to some or all members of the cohort,
as well as messages regarding individual research results.12
This design allows participants to be contacted as necessary by
researchers and as desired by each participant.13
Selecting and processing complex medical data for the full
socioeconomic diversity of participant populations presents ethical, legal, and social challenges, and demands numerous forms
of safety nets for the participants, ranging from ethical assessment by parties other than researchers, to structural mechanisms and sensors to detect harm and outreach to mitigate it.
Because of the expertise required, and our belief that some degree of integration with researchers themselves is necessary to
shape and implement structural safety nets, we have proposed
a governing body outside of the Institutional Review Board
(IRB), but nonetheless matrixed organizationally with it, to offer guidance regarding when genetic research results should be
returned to study participants.14 Kohane et al. proposed an Informed Cohort Oversight Board (ICOB) as a governance structure essential for the Informed Cohort to ethically return research results to participants while respecting autonomy.15 The
ICOB is envisioned as a body related to the IRB, but including
expertise in risk communication and genetic counseling, that
deals with what information is worthy of communication, how
best to communicate it without confusing or overwhelming participants, and how to help participants choose what knowledge
they want to receive and how they want to receive it.16 In the
Informed Cohort, individual research results are “broadcast” to
participants based on the “subject’s stated categorical preferences for information and the ICOB’s study-specific determination about what information can be effectively communicated in

11. Id.
12. Id.
13. Id.
14. See Timothy Caulfield et al., Research Ethics Recommendations for
Whole-Genome Research: Consensus Statement, 6 PLOS BIOLOGY 430, 431
(2008); Fabsitz et al., supra note 1 at 577; Ravitsky & Wilfond, supra note 6.
15. Kohane et al., supra note 9, at 836.
16. Id. at 836–37.
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a manner sensitive to subjects’ health literacy.”17 If “the characteristics, of the patient, genomic or clinical, match the characteristics of the patients described in the broadcast,” that patient participant will receive the message.18 In simplistic terms,
ICOB-approved results are returned to participants in accordance with their preferences. The decision-making process for
return of individual genomic information is consistent with the
“multidimensional results” three-dimensional reporting model
incorporating participant preferences, communicability, and
the significance of the result suggested in Kohane & Taylor.19
Our group at Children’s Hospital Boston has implemented
the Informed Cohort and ICOB within the framework of a
large-scale pediatric genomic study, The Gene Partnership
(TGP).20 TGP is a prospective longitudinal study at Children’s
Hospital Boston (CHB) designed to collect genetic information
on a large number of children who have been phenotyped, facilitating the study of genetic and environmental contributions to
childhood health and disease.21 The term “Gene Partnership”
reflects a partnership between researchers and participants.22
The stakeholder TGP participants are allowed to exercise their
autonomy by designating their preferences for what research
results to receive on themselves and their children.23 Key to
this process was developing the ICOB, which was created in
2009 to ensure that research results are conveyed in a clear,
accurate, and understandable manner, based in the first instance on enabled and educated participant choices, but with
due regard for potential harm.24 In this paper we describe the
values, structure, and guidelines for the return of results that
were developed by the TGP ICOB over the past two years. We
believe this framework is ethical, sustainable, scaleable, and
generalizable to large genomic research studies going forward.
17. Id. at 837.
18. Id.
19. Kohane & Taylor, supra note 2, at 3.
20. About TGP, CHILDREN’S HOSP. BOSTON, http://www.genepartnership
.org/about-tgp/ (last visited Feb. 10, 2012).
21. Erin D. Harris et al., The Beliefs, Motivations, and Expectations of
Parents Who Have Enrolled Their Children in a Genetic Biorepository,
GENETICS MEDICINE (Jan. 26, 2012), http://www.nature.com/gim/journal/
vaop/ncurrent/index.html#16022012.
22. About TGP, supra note 20.
23. See Kohane et al., supra note 9, at 837.
24. History, CHILDREN’S HOSP. BOSTON, http://www.genepartnership.org/
about-tgp/history/ (last visited Feb. 12, 2012).
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A. THE ICOB-CREATION PROCESS
Policies arise from processes, not fully fledged or like
Athena from the head of Zeus. We believe that honesty and respect for the opinions of others—especially where we are gently
questioning the abstract policy-creation of non-empiricallybased disclosure policies—requires that we frankly disclose
what, in science papers, would be called our “methods.” The
ICOB’s primary role in TGP, as we have seen it, is, through a
combination of infrastructure demands, general ethical policies,
and study-specific judgments, to act optimally to ascertain
whether individual research results can be conveyed in a clear,
accurate and understandable manner based primarily on enabled and educated participant choices, but with due regard for
potential harm.25 If results can be conveyed in such a way it is
the ICOB’s role to recommend such communication in a form
that maximizes communicability in accordance with preferences; and, if results cannot be communicated, to recommend
against communication.26 The latter might occur, for example,
because of a limitation on participant preferences, predicted
and unremediable harm or the impossibility of appropriate
communicability. It could also occur in the case of some pediatric results for adult-onset diseases, if an ethical conclusion sustainable without reference to empirical particulars is deemed to
bar it on the ground that respect for the eventual autonomy of a
child when she becomes adult is deemed to trump the parent’s
right to exercise the child’s autonomy during the child’s minority.
From the beginning, it was clear that implementing a vision of optimizing ethical reporting of communicable results
could not be reduced to editing messages any more than the
role of an institutional review board (IRB) can be reduced to idiosyncratic revisions to research informed consent documents.
To perform the function responsibly, the ICOB had to consider
and advise on the infrastructural and decisional components of
TGP that would ultimately affect participant experience, from
the nature of studies selected and results anticipated to the
characteristics of populations to be enrolled. It had to resolve
tensions between the desire to minimize individual harm by
25. See Kohane et al., supra note 9, at 837, Kohane & Taylor, supra note
2, at 2–4.
26. Id.
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maximizing individualized judgments and practical and ethical
concerns arising from the fact that ideal clinical and information technology supports are themselves co-evolving. It had
to address the probability that, within TGP, the primary results eligible for potential disclosure would not be known clinical variants incidentally discovered, but new and uncertain discoveries—novel variants, or novel understandings. The ICOB
also had to identify and address diverse sources of uncertainty:
an ethically divided field; IRBs skeptical of the value and communicability of genetic information or genetic research as a
whole; uncertainty about how to assess harm and benefit in the
context of our complete commitment to participants as people
who should be aided to make beneficial choices they were happy they made; the level, diversity and effects of health literacy;
evolving scientific interpretive standards for genetic information; and, indeed, the very organizational placement and
functioning of an ICOB.
As reflected in the gradual, step-by-step generation of policy documents, the trajectory of the ICOB is most succinctly described as a path from values to architecture, through respectful and inclusive deliberation. The architecture is best
described as a pyramid: on a foundation of values and principles of organizational placement is built an infrastructural policy which requires, for example, the TGP to establish mechanisms for educating participants concerning genetics and for
educating the ICOB concerning participant cohorts based on
surveys or other instruments; mechanisms of rapid impact assessment following messaging of validated results according to
putative preferences; rules for the ICOB to choose among various sorts of written and oral messaging appropriate to results
and sub-categorization of participants; and exceptions and “circuit-breakers” for situations of foreseeable harm. Essential to
establishing such policies was close communication with geneticists, informaticians, clinicians, ethicists, independent
thinkers brought in as advisers, and participants.27 The ICOB
deliberately invited the Director of Clinical Research Compliance (chief of the IRB staff) to join the committee, and always
included the faculty and professional staff of TGP itself, to keep
it grounded and well-informed, while deliberating independently.

27. For Experts, THE GENE PARTNERSHIP, http://www.genepartnership
.org/about-tgp/for-experts/ (last visited Feb. 13, 2012).
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By intention, members of the ICOB have diverse views
about how, when, and whether to communicate individual genetic results. Some, for example, disfavor results returned
based on skepticism about whether preferences are actually
durable, known by, and ascertainable from participants. Others
have heightened concerns about therapeutic misconception.28
Still others, including one of the authors of this paper, favor
broad disclosure of analytically valid information regardless of
whether its clinical significance is, in some views, certain.29
However, they believe that disclosure must be coupled (except
in rare cases) with disclosure of the radical uncertainty of genetic results generally when they stand alone without definitive analysis of the epigenetic, environmental, and behavioral
co-factors in gene expression, and without the unknown effect
of other genes that weak associations may reflect.30
Crucially, we have found these differences of perspective to
be fruitful and productive precisely because we have agreed to
set aside our theoretical, personal pet theories-as-certainties in
favor of a mutual commitment by ICOB members, and to use
our perspectives to fashion, test, and improve the optimal
method and infrastructure as a basis for fair empirical testing
and further conceptual scientific and ethical development and
revision by ourselves and by others. In abandoning the desire
to proclaim, enshrine, and defend indefeasible ethical certainties, we modeled our efforts on the more modest goal, daily pursued by both scientists and lawyers, of offering our work as a
building block to the community of knowledge, no more and no
less. Importantly, TGP is not merely a partnership between researchers and participants; it is a partnership between scientists, ethicists, scientific programs, and research ethics committees that is intended to benefit of participants by being
informationally transparent and decisionally independent, and
by building and improving an ethically responsive mechanism
for results reporting. While this has some of the disadvantages
of building and improving an airplane midflight, it also has
some of the advantages: responsiveness, sensitivity, avoiding
being marooned and ground-bound in a foggy airport, and an
28. Kohane & Taylor, supra note 2, at 2; Leslie A. Meltzer, Undesirable
Implications of Disclosing Individual Genetic Results to Research Participants,
6 AM. J. BIOETHICS 28 (2006).
29. Kohane & Taylor, supra note 2.
30. Id.
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engineering dedication to making sure the plane and passengers do not crash.
Having integrated education with policy development, the
ICOB is currently in its last phase: inducing consensus “hypotheses” for results return, based on close examination of hard
vignettes, involving starkly competing ethical and practical
concerns, within the multidimensional space described in
Kohane & Taylor.31 Our objective is not to arrive at the abstractly “right” principle; it is to arrive at the most likely and
beneficial hypotheses and subject them to testing.
In the future, the ICOB will be aided by three new inputs,
each implementing the theory that “this is a system that will
need to learn, as researchers and participants both learn from
it and create it together.”32 First, the TGP website will include
draft policy statements for participant comment, as well as information about the ICOB and its role.33 Second, the ICOB will
receive actual feedback on the consistency of its recommendations with participant preferences and resulting impact.34 We
believe this is a thoroughly novel approach for an ethics committee: neither IRBs nor conflict of interest committees, for example, learn of the correctness or consequences of their decisions. Third, the ICOB will be reviewed by a special advisory
committee, whose function will be much like blue ribbon scientific program review committees.
B. TRANSLATING VALUES AND GUIDING PRINCIPLES
The ICOB is charged with evolving oversight that maximizes respect for participant preferences with respect to the
scope and significance of results as a key variable in communication and is consistent with sound judgments about communicability of messages to recipients. To do so the ICOB must adequately identify and assess factors affecting communicability,
from message substance to messaging methods and recipient
characteristics. In an iterative manner the ICOB evaluates its
own and TGP’s judgments and modifies them based on experience and literature, identifying factors affecting the risks and
benefits of TGP and the Informed Cohort model, as variously
implemented. The ICOB strives for transparency, promotes col-

31.
32.
33.
34.

Id.
Id. at 3.
Id. at 3–4.
Id.
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laborative engagement with research participants and broader
inclusiveness in policy-making, and fosters public engagement
in genome-wide association studies—all are key to the ICOB’s
success.
C. ICOB STRUCTURE AND OVERSIGHT
The ICOB includes within its membership individuals with
professional training or expertise in one or more of the following areas: bioethics, genetics, medicine, law, and interpretation
and communication of probabilistic genetic results.35 One of the
ICOB members functions as chair. The ICOB shall also include
at least one professional genetic counselor.36 Additionally, the
ICOB will include individuals who, by personal experience or
profession, are able to represent or anticipate patient or participant perspectives.37 It may draw on the expertise of consultants to provide specialized expertise in diseases or conditions,
statistics, communications, or other matters as the ICOB
deems necessary after a discussion and vote. ICOB decisionmaking will be by consensus after reasonable discussion where
possible, and failing that, by formal vote.
In order to promote transparency and provide for input, an
ICOB Advisory Group will be convened whose members are
drawn from policy or program staff of the National Institutes of
Health (NIH), foundations and advocates for gene-specific conditions, and the professions represented on the ICOB. The
ICOB Advisory Group will review and provide feedback on proposed policies and pivotal decisions. Additionally, a web-based
method of posting public comments regarding significant policy
questions and proposed decisions will be developed in conjunction with TGP.
The ICOB has authority to make non-binding recommendations to TGP or its host hospital, Children’s Hospital Boston
(CHB). The ICOB is independent from TGP and from the CHB
IRB. TGP members are included in its meetings and discus35. See
Informed
Cohort,
THE
GENE
PARTNERSHIP,
http://www.genepartnership.org/about-tgp/informed-cohort/, (last visited Feb.
12, 2012) (“[W]e have developed . . . an Informed Cohort Oversight Board
(ICOB) made up of ethicists, scientists, physicians, genetic counselors, and
participant advocates to ensure safety and ethics throughout the partnership
process”).
36. Id.
37. See id. (the ICOB will include “participant advocates”).
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sions except in extraordinary circumstances where it convenes
to discuss a matter of special concern where an inclusive approach would necessarily constrain discussion. The ICOB is also independent of the CHB IRB. The ICOB reports its recommendations and conclusions to the IRB if requested by the IRB
or TGP, or at its own discretion. It is specifically recognized
that by law the IRB is independent and authoritative on certain matters within the scope of ICOB functions.38 However,
the ICOB is uniquely placed to formulate sound and influential
recommendations, and it is anticipated that TGP will be responsive to ICOB recommendations. The ICOB also retains the
right to communicate concerns to the IRB, and the IRB is expected to pay serious attention to ICOB concerns, particularly
with respect to participant harm or benefit. The ICOB is selfobligated over time to establish and modify policies addressing
messaging, the form and content of information required from
TGP and participating studies in order to perform ICOB functions, and evaluation of messaging and TGP vision in practice.
D. THE ICOB POLICY ON RETURN OF INDIVIDUAL RESEARCH
RESULTS
Formulating optimal methods for informing participants in
genetic and genomic research about individual research results
consistent with the Informed Cohort proposal, if done well, upholds the values of reciprocity, partnership, joint interest in
knowledge discovery that it seeks to translate into practice,
participant welfare, and the potential motivating effect it may
have on enrollment by subsequent participants. Historically,
the issue of returning research results has raised numerous
questions, many of which are focused on avoiding harm.39 However, this encompasses a range of concerns, including the validity of the results and their meaning and communicability for
any purpose in the context of studies of genes and conditions of
unknown or partially known significance.40 Additionally, uncer38. 45 C.F.R. § 46.109 (2010).
39. See Ebony B. Bookman et al., Reporting Genetic Results in Research
Studies: Summary and Recommendations of an NHLBI Working Group, 140A
AM. J. OF MED. GENETICS 1033, 1034 (2006) (“Psychological and social harm,
as well as financial costs and risks, may result from providing information
with significant implications for the health of the individual and his/her family
members.”).
40. See Ravitsky & Wilfond, supra note 6, at 11 (“An appropriate threshold of clinical validity is necessary to establish clinical utility because disclosure of results that have very uncertain meaning has little justification. Lim-

008 HOLM TAYLOR_PROOF -SK.DOCX (DO NOT DELETE)

680

MINN. J. L. SCI. & TECH.

7/5/2012 1:18 PM

[Vol. 13:2

tainty remains about the ability of research participants to understand and integrate research-related information, particularly if it is conditional and is delivered apart from participants’
clinical care history and providers.41 There are also contextual
differences from clinical genetic testing, in which patients are
already known or suspected to have a given condition are tested following counseling, and often receive their results through
personalized attention by highly trained professional genetic
counselors or geneticists.42 Thus, creating an optimal messaging policy necessarily implies creating mechanisms to address
these concerns in an evidence-based way.
The desire to provide such information in accordance with
participant personal preferences has added additional dimensions to the problem since the reliability and precision of stated
preferences are open to question. It is not clear that participants, let alone researchers, really know the ‘results’ participants seek since participants tend to define results in terms of
utility or pertinence, and there is significant evidence that
stated choices and actual preferences do not necessarily
match.43 The skepticism over participants truly understanding
the implications of their choice of which research results to receive suggests to some that it is unrealistic to incorporate participant preferences in return of research results and that doing so may in fact lead to harm. Alternatively, as with other
aspects of medicine, we may resolve questions of benefit, up to
a point, by acknowledging that it is the participant who is in
the best position to assess personal benefit, and that providing
information in accordance with participants’ autonomous choices is therefore beneficial.44 As required by law, the ICOB chose
ited clinical validity can also result in unnecessary procedures or anxiety.”).
41. See Conrad V. Fernandez, The Return of Research Results to Participants: An Ongoing Debate Modeled in Cancer Research, 8 HARV. HEALTH
POL’Y REV. 16, 25 (2007) (recommending that results that are returned to participants be “understandable and accessible to the lay public”).
42. See How Does Genetic Testing in a Research Setting Differ From Clinical Genetic Testing?, GENETICS HOME REFERENCE (Feb. 6, 2012),
http://ghr.nlm.nih.gov/handbook/testing/researchtesting (highlighting the key
differences between genetic testing in a research setting versus a clinical setting).
43. See, e.g., Grosse, supra note 7, at 121 (“New metrics are needed to assess personal utility, including quantitative methods to assess people’s preferences over various aspects of the genetic counseling and testing processes and
both medical and non-medical outcomes.”).
44. See Fabsitz et al., supra note 1, at 577–78 (recommending that inves-
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to apply the same principle to parents’ choices for their children, recognizing that the outside point at which the principle
fails is marked by obligations to prevent abuse and neglect.45
The proper parental role is further obscured by the existence of bioethics literature that contrasts parents’ involvement
of their children in research with parents’ clinical choices.
Questions have been raised about the ethics of parental decision-making resulting in a life-long impact for their child, when
such decisions could have been delayed until the child reached
adulthood.46 Such decisions may interfere with the child’s “future autonomy.”47 Further complicating matters, the relevance
of personal preferences for receiving negative information to resilience against negative information is also unknown. If there
was a direct relationship, then there would be reasons for soliciting and understanding the preferences of children that go beyond the ethical and legal supports for minor assent in research, and minor consultation—or in narrow circumstances,
consent—for clinical care. In that event, researchers could minimize harm by disclosing accordingly. The pediatric context
raises additional issues involving who consents and who receives intended genetic results. These are matters for IRB resolution, not ICOB recommendation, but they directly affect the
ICOB’s key charge to help engineer optimal disclosure processes, create testable guidelines, and oversee and improve messaging based on experience.
The very concepts of harm and benefit are poorly defined to
date. The genetic counseling profession has no established outcome measures, nor measures comparing personal counseling
to alternative methods, let alone methods that allow one to control for whether genetic results are favorable or unfavorable.
Established practice for delivering results is an intuitive art in
which integration of certain professional values, including sensitivity in face-to-face communications, is the norm. Whether it
is actually the most effective possible form of communication—
tigators may choose to return genetic research results to participants if they
indicate in the informed consent process their preference to receive such results).
45. 46 C.F.R. § 46.408 (2010).
46. See Kyle Bertram Brothers, Biobanking in Pediatrics: The Human
Nonsubjects Approach, 8 PERSONALIZED MED. 71, 77 (2011) (“[G]enetic testing
in children to identify risk for an illness that does not develop until adulthood
is controversial, since no medical harm will result from delaying testing until
the child can decide about testing when he or she reaches adulthood.”).
47. Id.
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let alone the only effective form—for all kinds of cases is unknown.
The landscape is complex, and the analytic tools to manage
some issues are in their infancy. The development of optimal
principles and approaches to messaging in the context of so
much uncertainty is therefore a process of discovery and refinement. TGP is an engineering work-in-progress, and its
leaders, the IRB, and investigators conducting studies under its
aegis, will need both immediate and long-term results about its
impact to use those results for process improvement. TGP must
be able to reassure itself and others, such as the IRB, that the
mode and content of results communication is accurate and
consistent with participant preferences and generally limited to
emotional harms that a participant, on balance, has accepted
as the price of desired knowledge. This means that an ethical
messaging policy inevitably has infrastructural implications.
E. RETURN OF INDIVIDUAL RESEARCH RESULTS–THE REQUIRED
INFRASTRUCTURE
Genetic associations are no stronger than the studies that
yield them, and studies must be adequately powered and structured to support the associations they purportedly uncover.
TGP needs to be assured, through the application process for
proposed studies using TGP, of the quality of the study to yield
anticipated findings. The results of that assurance and the nature of the study methods should be available to the ICOB in
reviewing a proposed disclosure to participants. While it is not
presently the standard to control the numerous variables that
could affect gene expression, and thus the reported gene associations ranging from epigenetic to environmental factors, TGP
should encourage studies that investigate these variables. Scientific reasons aside, understanding these factors may be as
valuable to participants as whether a condition is medically
treatable. Simple numerical probabilities that compare an individual’s fate to a sampled population, without considering factors that could affect gene expression, may cloak ignorance
about causation with an appearance of definite knowledge and
inevitable randomness.
Identifying participant preferences, capabilities, and vulnerabilities will require new approaches to understanding participants that are better than genetic research has previously
required. In an ideal world, investigators should be able to
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characterize the health literacy, motivations, care experience,
and vulnerabilities of the populations they seek to enroll. TGP
has conducted general surveys and focus groups with parents of
developmentally disabled children48 that proved extremely useful, suggesting that surveys, focus groups, or some other effective mechanism for understanding the range of participant
preferences, goals, and other characteristics should become a
foundation for subsequent TGP studies as a tool to understand
what parents who seek research results seek and what they
fear most.
Of course, not all potential participants are the same. Ultimately, whether it is appropriate to send an electronic message versus direct oral contact with a participant may depend
upon specific factors evident in the family’s or child’s history of
clinical care and may be associated with additional resilience.
Such information may help inform whether and how to message specific families. Furthermore, a comprehensive and reliable process for routinely obtaining and considering such information would provide a basis for an IRB to conclude that TGP
had appropriately linked the methods of results disclosure with
context-dependent potential harm. Without being prescriptive,
more broadly pursuing the various methods by which electronic
medical information could be available in useable or flagged
form to investigators, TGP and the ICOB could distinguish categories and signals for distinct harm requiring distinct communication approaches. Currently, the pace of electronic records becoming accessible for use is outside the control of TGP.
Other means to explore may include special inquiries through
the PCHR or special inclusion or exclusion criteria that, in effect, identify those who may be expected to have special vulnerability to possible information anticipated from a study.
Such data are too pertinent to results disclosure and its communicability to ignore, even if the infrastructure to extract it
and interpret it is in development. Investigators proposing TGP
studies will require a factual basis for assuring the IRB that
risks to participants have been minimized; they will only be
able to do so if TGP has assumed a more systematic responsibility of managing and understanding these risks.
Collecting and integrating impact information is crucial to
the success of the ICOB and return of results. After returning
any research result, participant written feedback should be
48. Harris et al., supra note 21, at 2.
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immediately solicited, perhaps through an automated PCHR
email process directed to the participant’s understanding of the
results and questions or concerns of any type. The process
should also identify families in need of direct interventions given their responses, which may necessitate breaking the anonymity. Feedback data should be presented to the ICOB for
oversight and quality improvement purposes. It will be important to understand whether a participant is unhappy solely
because of the content but does not regret the message, its
method, or seeking it, and whether the participant believes her
or his preferences were misread. It is also important to assess
whether additional participant questions should have been anticipated and addressed in a message and whether the message
was mis-categorized with respect to form of delivery. Clusters
of negative impact should trigger immediate review and action.
In that case, the ICOB will work with TGP on methods of direct
inquiry, including those participants who were, and were not,
negatively affected.
The ICOB should have a program for periodic selfevaluation. Evaluating message impact is important and cannot be done thoroughly without evaluating the means by which
message decision-making is made. Tools to determine the consistency of messages for given categories, if they address only
genetic associations, will be useful for what they teach about
the appropriateness of given categories. If the tools also address participant data, they will teach about the appropriateness of a message where impact data will be of primary importance. Rectifying messaging mistakes may require better
data, better assessment algorithms, changes in infrastructure,
and changes in enrollment and communication. The ICOB will
bring any concerns and recommendations concerning human
subject protections or the clinical research process for a study,
such as the participant’s misunderstanding of an informed consent document, to the attention of TGP and the IRB.
II. RETURN OF INDIVIDUAL RESEARCH RESULTS –
PRINCIPLES
A. ACCURACY IN CONTEXT
Genetic associations must be communicated in context and
be appropriately conditional. Meaning, rather than presenting
an abstract association or probability, the association will be
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presented in the context of the methods of the study that produced it, any corroborative studies, consistency or inconsistency
with other studies, and its limitations (e.g., study basis, available family genetic information, degree of peer reviewed confirmation, possible influence of other genes, degree to which environmental influences are identified, etc.).
B. A PROGRAM OF EDUCATION
CHB’s web-based program for parents on pediatric research shows that well-executed educational materials can enable parents to understand many complex issues, and therefore
make more informed and satisfactory choices when considering
participation in research. Two such programs should be created
by, and for, TGP. The first should be used during enrollment
and specifically focus on TGP and issues involved in receiving
individual research results, including how to approach making
key choices—from the choice to enroll to choosing the sorts of
results desired. The second should always be available to enrollees on a TGP web site, should be linked to each message, and
should explain how to interpret the results they receive. Substantive updates about research results overall, new forms of
research, and the status of particular studies should also be
communicated to the general participant population. But most
important is teaching both the basis and limitations of genetic
interpretation.
C. SHARED RESPONSIBILITY FOR PROCESS AND RESULTS:
The investigator: Potentially reportable content should
originate with the investigator, who will present a detailed description of the research result to TGP, explaining its basis and
including a judgment of its significance to a participant or a
subset of participants. The investigator is expected to provide
supporting evidence for the reported finding, including: a) a
clear description of phenotypic effect and personal impact of
finding; b) the study design, methods, and analysis; c) the
strength of the association and degree to which condition emergence depends upon other genetic, environmental, or other
modifying factors; d) the strength of the evidence for association in light of peer-reviewed literature; e) numerical risk estimate(s); and f) references to scientific publications and resources relevant to the finding. The investigator may also
propose a draft message but is not required to.
TGP: Investigator-reported findings will be evaluated by
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TGP and used as the basis for the proposed message. In a written report to the ICOB, TGP should communicate its agreement or disagreement with each of the elements reported by
the investigator, and also address the: a) degree of risk, b) certainty of the findings, c) known impact on persons affected and
any variability in such impacts, and d) specific actionability
(including the form, availability, and effectiveness of preventive
and/or therapeutic methods). The TGP report should also propose classifications, as described below, and draft messages
consistent with the classifications. TGP draft messages should
be consistent with any applicable ICOB policies and with identifying information about the participants that is pertinent to
preferences and vulnerabilities gathered from data provided
from, or about, participants through the research-associated
PCHR, surveys, focus groups, and other sources available. The
proposed message or messages should be accompanied by educational or other materials designed to ensure that the message
will be understood by the intended recipients.
ICOB: The ICOB should evaluate the recommendation and
concur or disagree, stating its reasons for doing so in writing or
in the minutes and communicating accordingly with TGP. The
ICOB may also approve messages conditioned on modifications
to proposed messages.
D. PROMPT REVIEW OF PARTICIPANT FEEDBACK
Feedback should be collected by TGP and concerns should
be immediately conveyed to ICOB members and the investigator. The ICOB may recommend certain steps to the investigator
and TGP, and may withdraw or modify approval previously
given. It remains the investigators’ primary responsibility, consistent with applicable regulations and IRB directives, to take
appropriate action to address participant harms. The role of the
ICOB shall not dilute that responsibility. The ICOB shall communicate to the IRB on whatever issues the IRB designates.
E. MESSAGE CATEGORIES
Until new categories are created through experience, messages should be categorized at each stage (by the investigator,
TGP, and the ICOB) as follows: 1) In the case of messages of
extraordinary importance, the results will be provided regardless of the participants’ stated preferences. This requires that
the participants be proactively identified, and that genetic

008 HOLM TAYLOR_PROOF -SK.DOCX (DO NOT DELETE)

2012]

7/5/2012 1:18 PM

THE INFORMED COHORT OVERSIGHT BOARD

687

counselors or clinicians reach out to them regardless of participant preferences. 2) Most messages are expected to be congruent with preferences, in which case they are returned in accordance with the participants’ preferences. 3) There may be
cases in which participants’ preferences are followed but a cautionary note is sent to the participant asking “are you sure”
with some context to enable participants to make a situationspecific choice.
Different forms of communication may be required depending on the message. For some messages, personal oral communication of results will be deemed unnecessary and an appropriate written message will be adequate. On the other hand,
there will be messages in which personal oral communication of
results is always necessary for first disclosure, and the need for
personal oral communication may depend on participant characteristics. For all written disclosures, personal oral communication with genetic counseling must be available on request following the disclosure.
III. ICOB GUIDELINES FOR RETURN OF RESULTS
The guiding principles for the ICOB in the disclosure of individual research results to TGP participants are: 1) to protect
participants from disclosure of results that may lead to harms,
and 2) to return results that are consistent with the participants’ preferences. Potential harms in return of results include
returning results that are not scientifically “sound” (i.e., lack of
analytic validity) or are not clinically “meaningful” (i.e., lack of
clinical validity), loss of the future autonomy of a child (vulnerable population), discoveries that pose imminent risks of severe
harm to families that can be prevented by nondisclosure (e.g.,
mis-identified paternity), lack of communicability, and returning results that are inconsistent with participant preferences.
The ICOB has identified strategies to return individual research results that reduce or eliminate these harms. Careful
advance review of studies proposed for inclusion in TGP is especially important to guarantee the validity and precision of
potential results. A commitment to analytic validity requires
that studies are performed in a CLIA-certified laboratory before
returned to participants. The ICOB will specifically consider
the mode of communication, including considering the role of
genetic counselors throughout the entire return of results process. The contextualization of results will be important (e.g.,
limitations on conclusions given lack of knowledge about envi-
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ronmental influences). A process of immediate follow-up and
querying, combined with an offer of genetic counselor involvement for further questions or concerns and maintaining a philosophy of working incrementally and iteratively in response to
feedback, will be critical to assure that no harm is done, and, if
there is harm, to detect it.
The issue of the child’s future autonomy deserves special
consideration, in particular as TGP is a study of childhood
health and disease. Capable adult participants make preference choices for themselves, but parents make preference
choices for their children. However, as children grow towards
being fully independent at eighteen years of age, this developing autonomy must be considered. To this end, the ICOB and
TGP have adopted the policy that capable adolescent participants and their parents make preference choices for children
thirteen to eighteen years of age. But what if the parental and
adolescent preference choices are not congruent? In these cases
the adolescent participants’ disclosure choices trump parental
choices, thus acknowledging the adolescent’s right to his or her
future autonomy. It should be noted that there are exceptions
to adhering strictly to parent and/or adolescent preferences.
Discoveries that implicate the child’s future “sphere of privacy”
life planning (adult onset conditions that are not treatable,
nonmedical traits, etc.), and discoveries that implicate the
child’s future reproductive risks, are not disclosed until the
child participant is eighteen years of age (or is an emancipated
minor in the case of reproductive risks) and only if the participant chooses disclosure.
Using these principles, individual research results must be
analytically valid and meet a threshold of clinical validity for
return. Individual research results that are not analytically or
clinically valid—as determined by a Scientific Review Group
assessment—will not count as “discoveries” which TGP participants can elect to learn about themselves. Individual research
results must be communicable—able to be contextualized in
adequate education and counseling. Results that are not communicable to patients in a clear way will not count as “discoveries” which TGP participants can elect to learn about themselves
based on a genetic counseling assessment.
There may be times when participant preferences are overridden. Although this situation is likely to be rare, some consideration must be taken for this possibility. Discoveries that
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predict imminent risks of severe harm that can only be prevented by disclosure (juvenile leukemia) may be disclosed regardless of participant preferences. If adult participants decline disclosure of discoveries that predict risks of preventable harm to
children, the discoveries may be disclosed to third parties
(treating physicians). On the flip side, discoveries that pose
imminent risks of severe harm to families that can be prevented
by nondisclosure (e.g., mis-identified paternity) may not be disclosed, regardless of participant preferences. Finally, discoveries that pose risks of harm may be disclosed to some of those
families implicated, but not others, and only to some family
members (parents/child/spouse), but not others, depending on
the nature of the discovery and what screening metrics of “resilience” or “vulnerability” are available.
CONCLUSION
In daily life, we learn that there is often more than one potential “right” answer. What is “right” may depend upon known
or unknown factors, not simply because utilities depend on circumstances, but because the genuine applicability of nonconsequential ethical theories will depend upon practical realities. Just so, we argue, when it comes to considerations of the
harms and benefits that come from disclosing research results.
Just so also when one argues that the burdens of disclosure will
be unmanageable or that therapeutic misconceptions are inevitable and outweigh any possible benefit. Such assertions necessarily depend upon unstated assumptions that these challenges
are invariable, change is impossible, and we live in, if not the
best of all possible worlds, one of fixed and necessary limitations that foreclose any alternative universe. In offering a model of ICOB policies and processes, we do not claim that we have
offered the only “right” ones. Instead, we claim only that limiting assumptions calls out for identification and testing; that
testable ethical hypotheses—beginning with classical ethical
thinking but not ending there—can be formulated, and that
formulating and testing such hypotheses about what is right or
wrong with respect to individual results disclosure reflects devotion to the personhood of research participants, translating
values into testable behaviors.
The ICOB is a governance mechanism, and a particularly
influential one in part because of, not despite, its communicative integration with scientists, the IRB, and research partici-
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pants who are, through its means, empowered to speak for
themselves about preferences, benefits, and harm. Governance
over return of individual research results is complex with a
multitude of ethical, legal, and social challenges to face. Over a
two-year period, the ICOB for TGP has wrestled with many of
these challenges and derived a framework from which to address the challenges. As individual research results are generated in TGP, the framework will be tested and modified, as
there is no better test than putting the framework into practice.

